Oncotelic Therapeutics Files 8-K on Agreements
Ticker: OTLC · Form: 8-K · Filed: Dec 9, 2025 · CIK: 908259
| Field | Detail |
|---|---|
| Company | Oncotelic Therapeutics, Inc. (OTLC) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $25,000, $0.10, $1.00, $0.12, $1.25 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, financials
TL;DR
Oncotelic Therapeutics filed an 8-K on 12/4/25 covering new deals and equity sales.
AI Summary
On December 4, 2025, Oncotelic Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company, formerly known as Mateon Therapeutics Inc. and Oxigene Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.
Why It Matters
This 8-K filing indicates significant corporate activity, including new agreements and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — 8-K filings often signal material events, but the specific nature of the agreements and equity sales requires further analysis to determine the precise risk level.
Key Players & Entities
- Oncotelic Therapeutics, Inc. (company) — Registrant
- Mateon Therapeutics Inc. (company) — Former Company Name
- Oxigene Inc. (company) — Former Company Name
- December 4, 2025 (date) — Date of earliest event reported
- 20251204 (date) — Conformed period of report
- 20251209 (date) — Filing date
FAQ
What specific material definitive agreement was entered into by Oncotelic Therapeutics, Inc. on December 4, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales mentioned in the 8-K?
The filing mentions unregistered sales of equity securities, but the type and details of these securities are not specified in the provided text.
What are the key financial statements and exhibits included with this 8-K filing?
The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When was Oncotelic Therapeutics, Inc. formerly known as Mateon Therapeutics Inc. and Oxigene Inc.?
The company was formerly known as Mateon Therapeutics Inc. with a date of name change of June 13, 2016, and formerly known as Oxigene Inc. with a date of name change of June 28, 1993.
What is the principal executive office address for Oncotelic Therapeutics, Inc.?
The principal executive offices are located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301.
Filing Stats: 1,054 words · 4 min read · ~4 pages · Grade level 11 · Accepted 2025-12-09 17:01:08
Key Financial Figures
- $25,000 — he "Notes"), in the principal amount of $25,000.00, bearing annual interest at the rate
- $0.10 — otelic's Common Stock (conversion price $0.10 per share) or 25,000 shares of common s
- $1.00 — ned subsidiary at a conversion price of $1.00 per share, both subject to applicable a
- $0.12 — ne share of Oncotelic's Common Stock at $0.12 per share or 25,000 warrants (the " Edg
- $1.25 — mmon stock of EdgePoint Common Stock at $1.25 per share. The exercise price of each W
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 148KB
- ex10-2.htm (EX-10.2) — 7KB
- ex10-3.htm (EX-10.3) — 88KB
- ex10-4.htm (EX-10.4) — 78KB
- ex10-5.htm (EX-10.5) — 115KB
- ex10-2_001.jpg (GRAPHIC) — 1111KB
- ex10-2_002.jpg (GRAPHIC) — 1364KB
- ex10-2_003.jpg (GRAPHIC) — 1365KB
- ex10-2_004.jpg (GRAPHIC) — 1055KB
- ex10-2_005.jpg (GRAPHIC) — 1507KB
- ex10-2_006.jpg (GRAPHIC) — 1371KB
- ex10-2_007.jpg (GRAPHIC) — 552KB
- 0001493152-25-026883.txt ( ) — 12186KB
- otlc-20251204.xsd (EX-101.SCH) — 3KB
- otlc-20251204_lab.xml (EX-101.LAB) — 33KB
- otlc-20251204_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
02 below,
Item 3.02 below, Item 3.02 Unregistered Sales of Equity Securities. On December 4, 2025, Oncotelic Therapeutics, Inc. (the " Company ") completed entering into subscription agreements with certain accredited investors (" Subscription Agreement "), whereby the Company issued a total of 11 units (" Units "). Each Unit is part of an offering (the " Offering ") of up to Five Hundred (500) Units being conducted by the Company. Each Unit consists of one note issued by the Company (a "Note" and collectively, the "Notes"), in the principal amount of $25,000.00, bearing annual interest at the rate of 12% and due and payable on the 2-year anniversary of the final closing of the Offering. Each Note will be convertible into up to 250,000 shares of Oncotelic's Common Stock (conversion price $0.10 per share) or 25,000 shares of common stock (" EdgePoint Common Stock ") of EdgePoint AI, Inc. (" EdgePoint "), our consolidated minority owned subsidiary at a conversion price of $1.00 per share, both subject to applicable anti-dilution provisions. Each Unit will also consist of 250,000 (the " Warrants ") each to purchase one share of Oncotelic's Common Stock at $0.12 per share or 25,000 warrants (the " EdgePoint Warrants ") to purchase each one share of common stock of EdgePoint Common Stock at $1.25 per share. The exercise price of each Warrant or EdgePoint Warrant will be subject to applicable anti-dilution provisions set forth therein and, except as set forth in the next succeeding sentence, each Warrant will be exercisable for two years after issuance. The Units are being offered to investors in the Company's 2023 PPM Note as well as new investors. For investors in the 2023 PPM Note, the investor can receive their Units in exchange for the Company's 2023 PPM Note, the Company shall consider the old 2023 note as paid off and the contribution towards the new Units as fully paid for, with all the terms noted above. The prior warrants issued in connection with the 2023 PPM Notes